Abstract 11695: The Kinetics of Circulating Monocyte Subsets and Microbial Translocation in the Acute Phase of ST-Elevation Myocardial Infarction Reveals Prognostic Values for Cardiovascular Outcomes
Introduction: In experimental myocardial infarction (MI), a rise in cell counts of circulating monocyte subsets contributes to impaired myocardial healing, and to atherosclerotic plaque destabilization.The underlying pathophysiological mechanisms for the post-MI monocytosis and the prognostic role of monocyte subsets in patients suffering ST-elevation MI (STEMI) are still unclear.
Hypothesis: The kinetics of the three monocyte subsets (classical CD14++CD16-, intermediate CD14++CD16+ and non-classical CD14+CD16++ monocytes) and gut microbial translocation are associated with cardiovascular outcomes after STEMI.
Methods: In 100 STEMI patients treated with primary percutaneous coronary intervention (PCI), monocyte subsets and microbial translocation markers (lipopolysaccharide [LPS] and D-lactate) were measured on Days 1, 2, 3, 5 and 7 of STEMI onset, compared with 35 stable coronary heart disease patients and 35 healthy volunteers. All STEMI patients were prospectively followed for the first occurrence of an adverse cardiovascular event.
Results: From Day 1 to Day 7, a parallel increase in CD14++CD16- cell counts, CD14++CD16+ cell counts, and gut permeability markers was observed, with peak levels on Day 2. During a median follow-up of 1.5 years, 25 events were recorded. Univariate Kaplan-Meier analysis revealed that Day 2 CD14++CD16- cell counts (P=0.022), CD14++CD16+ cell counts (P =0.024) and Δ LPS (Day 2 – Day 1; P=0.027) each predicted the primary endpoint when stratified by median values. After adjustment for confounders, Day 2 CD14++CD16+ monocyte counts showed the strongest predictive value (per SD increase: hazard ratio [HR]: 2.127; 95% CI 1.313 to 3.446; P=0.002) for cardiovascular events.
Conclusions: The expansion of the CD14++CD16+ monocyte subset on Day 2, which is associated a transient increase in microbial translocation, independently predicts adverse cardiovascular outcome in STEMI patients treated with primary PCI.
Author Disclosures: X. Zhou: None. X. Liu: None. W. Ji: None. D. Ren: None. Z. Guo: None. Y. Ma: None. Z. Zhang: None. E.B. Thorp: None. B.C. Benefield: None. D.C. Lee: None. J. Zhao: None. A.M. Zawada: None. Y. Li: None. G.H. Heine: None.
- © 2015 by American Heart Association, Inc.